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Abstract
Background—Race- and gender- specific epidemiology of incident heart failure (HF) in a
contemporary elderly cohort is not well described.
Methods—We studied 2934 participants without HF enrolled in the Health ABC Study (age 73.6
±2.9 years, 47.9% men, 58.6% white, 41.4% black) and assessed incidence of HF, population
attributable risk (PAR) of independent risk factors for HF, and outcomes of incident HF.
Results—During a median follow-up of 7.1 years, 258 (8.8%) participants developed HF
(13.6/1000 person-years). Men and blacks were more likely to develop HF. No significant sex-based
differences were observed in risk factors. Coronary heart disease (whites: PAR 23.9%, blacks: PAR
29.5%) and uncontrolled blood pressure (whites: PAR 21.3%, blacks: PAR 30.1%) carried the highest
PAR in both races. In blacks, 6 out of 8 risk factors assessed (coronary heart disease, uncontrolled
blood pressure, left ventricular hypertrophy, reduced glomerular filtration rate, smoking, and
increased heart rate) had >5% higher PAR compared to whites, leading to a higher overall proportion
of HF attributable to modifiable risk factors in blacks vs. whites (67.8% vs. 48.9%). Participants who
developed HF had a higher annual mortality (18.0% vs. 2.7%). No racial difference in survival after
HF was noted; however, rehospitalization rates were higher in blacks (62.1 vs. 30.3/100 person-years,
P<.001).
Conclusions—Incident HF is common in the elderly; a large proportion of HF risk was attributed
to modifiable risk factors. Racial differences in risk factors for HF and in hospitalization rates after
HF need to be accounted for prevention and treatment efforts.
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Heart failure (HF) is primarily a disease of the elderly, with an annual incidence of 10/1000
after age 65 years, which doubles every decade thereafter.1 Subjects older than 65 years
represent >75% of prevalent HF cases in the United States.2 In a recent European study,
participants older than 70 years accounted for 88% of new HF cases.3 Although some data
suggest a relative improvement in survival after development of HF recently,4, 5 other studies,
especially in the elderly, challenge this notion.6 Nevertheless, the absolute survival rate for
these patients remains poor and the actual number of HF deaths has increased by 20.5% over
the last decade, reflecting the increasing prevalence of HF and the aging of the population. In
patients older than 67 years, median survival is generally less than 3 years after hospitalization
for HF.7, 8 The annual hospitalization rate for these patients now exceeds over a million in the
United States, 80% of patients hospitalized with HF are older than 65 years, and readmission
rates as high as 50% within 6 months of discharge have been reported.9
Risk factors and outcomes for HF in the general population have been well described.4, 8, 10,
11 However, many of these data are old, derived from primarily white subjects, and mostly in
relatively young or middle-aged populations. The risk factor profile for cardiovascular diseases
is changing with increasing prevalence of obesity, metabolic syndrome, and diabetes.12
Similarly, the therapeutic profile for risk factors like hypertension or coronary heart disease
(CHD) has evolved over time, with increased use of ACE inhibitors and statins. This may affect
both the development of HF and outcomes thereafter. Also, recent literature suggests
substantial differences in disease development and progression among sex- and race-based
sub-groups.13, 14 Understanding and quantifying these differences is imperative for planning
appropriate preventive and therapeutic interventions. The sex- and race-related risk factor
profile and population attributable risk (PAR) for HF risk factors in the contemporary elderly
population are not known. In this study, we sought to assess the epidemiology of incident HF
in the elderly participants enrolled in the Health, Aging and Body Composition (Health ABC)
Study.
METHODS
Study Population and Outcomes
The Health ABC Study is a population-based study of 3075 community-dwelling men and
women aged 70 to 79 years at enrollment. To be eligible, participants had to report no difficulty
in walking one-quarter mile or climbing 10 stairs without resting. Participants were identified
from a random sample of white Medicare beneficiaries and all age-eligible black community
residents in designated zip codes areas surrounding Pittsburgh and Memphis. Exclusion criteria
included difficulties with activities of daily living, obvious cognitive impairment, inability to
communicate with the interviewer, intention of moving within 3 years, or participation in a
trial involving a life-style intervention. All participants provided written informed consent and
the Institutional Review Boards at both study sites approved the study protocol.
Baseline data were collected in 1997–1998. Cardiovascular disease status at baseline, including
prevalent HF, was based on ICD 9-CM codes as reported by Medicare and Medicaid Services
for the years 1995–1998; self-reported history; and use of selected drugs. All participants were
asked to report any hospitalizations and every 6 months they were asked direct questions to
elicit information about interim cardiovascular events. All admissions with an overnight stay
were evaluated for cardiovascular events by reviewing the medical records at each site. All
hospitalizations and deaths were reviewed by the Health ABC Diagnosis and Disease
Ascertainment committee and underlying causes of death were determined by central
adjudication.
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Of the 3075 subjects enrolled at in the Health ABC Study, 95 had definite or possible HF at
baseline, and 46 were excluded due to missing data on HF status. The final cohort analyzed
for this study included 2934 participants.
Study Definitions
Incident HF—All first admissions with an overnight stay confirmed to be related to HF were
classified as incident HF. Local adjudicators classified events as HF, based on symptoms, signs,
chest radiograph results, and echocardiographic findings, using criteria similar to those used
in the Cardiovascular Health Study.15 Briefly, physician diagnoses of HF were confirmed by
documentation in the participants’ medical records of a constellation of symptoms (i.e.,
shortness of breath, fatigue, orthopnea, paroxysmal nocturnal dyspnea) and physical signs (i.e.,
edema, pulmonary rales, gallop rhythm, displaced left ventricular apical impulse) or by clinical
findings such as evidence of pulmonary edema on chest radiograph. Although ejection fraction
was not available for all incident HF hospitalizations, when it was available it was considered
part of the clinical picture. The diagnosis of CHF was also confirmed if, in addition to having
a physician diagnosis of HF, the participant was receiving medical therapy for HF, including
diuretics, digitalis, angiotensin-converting enzyme inhibitors, and beta-blockers.
The HF criteria required at least HF diagnosis from a physician and treatment for HF (i.e. a
current prescription for a diuretic agent and either digitalis or a vasodilator); these criteria have
been used in previous studies.16 Since HF was not allowed as a cause of death, there were no
deaths considered as due to incident HF.
Risk Factors Definitions—History of coronary revascularization, electrocardiographic
evidence of myocardial infarction, or self-reported history of myocardial infarction or angina
accompanied by anti-anginal medications was considered definite evidence of CHD; self-
reported history of CHD without medications was considered as probable CHD. Hypertension
was classified as definite if there was both a history of hypertension or physician diagnosis and
use of antihypertensive medications; history or medications alone were classified as probable
hypertension. Diabetes was considered present if the participant reported history of diabetes
or use of anti-diabetic medications. Smoking was classified as current, past (if ≥ 100 lifetime
cigarettes), or never. Cerebrovascular disease was based on history of stroke, transient ischemic
attack, or carotid intervention. Depression was defined as self-reported depression
accompanied by medication use. Left ventricular hypertrophy (LVH) was determined from the
baseline electrocardiogram by the following criteria17: R >26mm in either lead V5 or V6, or
R >20mm in any of leads I, II, III, aVF, or R >12mm in lead aVL, or R in lead V5 or V6 plus
S in lead V1 >35mm.
Risk Factors for Incident HF—We have previously reported independent predictors of
incident HF in the Health ABC Study.18 Nine variables were independently associated with
HF development: age, history of smoking and CHD, LVH, systolic blood pressure and heart
rate, and serum glucose, albumin, and creatinine levels; sex and race were both considered but
neither was independently associated with incident HF. For PAR calculation purposes,
continuous predictors were dichotomized using clinically relevant cut-off points. Systolic
blood pressure was dichotomized as controlled vs. uncontrolled at 140 mmHg, fasting glucose
at 125 mg/dl, resting heart rate at 75 bpm,19 and albumin at 3.8 mg/dl 20; creatinine was
converted to glomerular filtration rate (GFR) by MDRD formula 21 and a cut-off of 60ml/min/
1.73m2 was used to define impaired GFR. Smoking (current yes/no) and CHD status (definite
yes/no) were collapsed into binary predictors. We classified independent risk factors into two
groups: modifiable (CHD, systolic blood pressure, glucose, LVH and smoking) and potentially
modifiable (renal function, albumin, and heart rate). Age was included in regression models
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for multivariable PAR calculation, but PAR of age was omitted from the tables since age cannot
be modified.
Statistical Analysis
We compared continuous variables with the rank-sum test and categorical variables with the
Fisher’s exact test. Cumulative event rates were obtained with the Kaplan-Meier method and
compared with the log-rank statistic. Raw and adjusted hazard ratios (HR) and the
corresponding confidence intervals (CI) were obtained by Cox models. Interaction terms were
fitted where appropriate.
Because of the sampling approach of the Health ABC Study, the study sample is not
representative of the race distribution of the elderly population in the United States. Therefore,
we opted to calculate only race-specific PAR estimates, and did not calculate pooled PARs.
Sex-specific and sex-stratified (Mantel-Haenszel combined) rate ratio (RR) estimates for the
risk factors of interest were calculated. Unadjusted (univariable) PARs were calculated with
the standard formula 22:
This formula, however, is only valid when no confounding exists.23 Therefore, we also
calculated adjusted (multivariable) PARs using a Poisson regression model with incident HF
as the outcome and the factors described above as predictors.24 Briefly, the predicted number
of cases is calculated for the full model (N full) - which equals the actual number of cases. Next,
the effect of the risk factor of interest is “removed” by setting the value of the covariate to zero
and the predicted number of events is calculated (N removed). The adjusted PAR for the risk
factor becomes then:
Similarly, it is possible to calculate the total preventable fraction, i.e. the proportion of cases
that could be prevented if these risk factors were eliminated, by setting all the covariates to
zero; notably, the sum of the individual PARs does not add up to the total preventable fraction.
Also, although maximum likelihood estimators have been shown to produce reliable point
estimates and CIs of PAR in simulation studies,24 no formal method to compare PAR for a
risk factor between groups has been developed to date.
Hospitalizations were analyzed as count data over time at risk; RRs and CIs were obtained by
Poisson regression. All analyses were performed with Stata 10.0. Adjusted PARs were




The mean age of participants was 73.6±2.9 years; 47.9% were men and 58.6% white. After
7.1 years median follow-up (25%–75%, 6.6–7.5 years), 258 participants (8.8%) developed HF
(annual rate: 1.36%, 95% CI, 1.21%–1.54%). The baseline characteristics of participants are
presented in Table 1. Figure 1 presents the Kaplan-Meier estimates of incident HF in race- and
sex-based subgroups; men and blacks were more likely to develop HF than women and whites.
Annual rate was 1.63% in black vs. 1.19% in white participants (age-adjusted HR: 1.41, 95%
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CI, 1.11–1.80, P=.006); and 1.58% in men vs. 1.17% in women (age-adjusted HR 1.34, 95%
CI, 1.05–1.71, P=.021). Sex-race interaction term was not statistically significant (P=.470).
Population Attributable Risks
Tables 2 and 3 present the prevalence and the unadjusted (univariable) and adjusted
(multivariable) PARs for the independent risk factors. Increased systolic blood pressure, heart
rate, and fasting glucose levels, LVH, smoking, and decreased albumin levels, all were more
prevalent in blacks than whites (P<.001 except for heart rate P=0.005 and albumin P=.01). In
contrast, decreased GFR was more prevalent among white participants (P=.001). Prevalence
of CHD was comparable across race (P=.48). The preventable fraction due to modifiable risk
factors was 48.9% in whites (95% CI, 35.1%–59.8%) vs. 67.8% in blacks (95% CI, 55.1%–
76.8%). Uncontrolled systolic blood pressure and CHD had the higher PARs (>20%) in both
race groups both in unadjusted and adjusted analyses. Adjusted PARs for all independent risk
factors except serum glucose were higher in blacks than whites with LVH, smoking, and GFR
<60 ml/min/1.73m2 being approximately 10% higher.
Outcomes After Incident HF
During a median of 2.1 years (25%–75%, 0.7–4.4 years) after initial hospitalization for HF,
121 of 258 participants with HF died (46.9%), representing an 18.0% (95% CI, 15.0%–21.5%)
annual mortality. In addition, 312 all-cause readmissions were recorded (46.3 per 100 person-
years); of these, 252 (80.8%, 37.4 per 100 person-years) were related to HF. In comparison,
participants who remained HF-free throughout the study had an annual mortality of 2.72%
(95% CI, 2.49%–2.97%) and a hospitalization rate of 21.9 per 100 person-years (RR 2.11, 95%
CI, 1.88–2.37, P<.001).
Table 4 summarizes the outcomes after incident HF in the race- and sex- based subgroups.
Overall survival did not differ between whites and blacks (log-rank χ2=0.00, P=.984), however
there was a significant race-sex interaction (white male vs. female HR: 0.70, 95% CI, 0.41–
1.21, P=.202, black male vs. female HR: 2.10, 95% CI, 1.23–3.60, P=.007, P=.015 for
interaction), Figure 2. Rates of all-cause rehospitalization were two-fold higher in blacks
compared to whites (62.1 vs. 30.3 per 100 person-years, RR: 2.05, 95% CI, 1.62–2.60, P<.
001). This effect was mainly due to HF-related readmissions: blacks had 53.2 HF-related
hospitalizations per 100 person-years compared to 21.3 for whites (RR: 2.50, 95% CI, 1.90–
3.30, P<.001). The differences in rehospitalization rates between race-based subgroups
persisted after controlling for age and number of concomitant conditions (data not shown). No
race-sex interaction was observed for all-cause and HF rehospitalization rates (P=.36 and P=.
71, respectively, for the interaction terms).
Data on ventricular function during hospitalization for HF were not prospectively collected in
the Health ABC Study; therefore, the available data are based on chart reviews. Data on left
ventricular ejection fraction (LVEF), obtained by either echocardiography or left
ventriculography reports during the index HF hospitalization, were available in 197/258
(76.4%) of participants. Median LVEF was 40% (interquartile range, 26–55) without
difference between the white and the black participants (median LVEF 40% for both groups).
However, LVEF was higher in female participants (median LVEF 46% vs. 35% in males, P=.
011); no race-sex interaction was observed. Participants with LVEF >40% (n=97, 49.2%) had
subsequent age-adjusted mortality 14.9, all-cause hospitalization rate 51.3, and HF
rehospitalization rate 38.6 per 100 person-years. In comparison, participants with LVEF ≤ 40%
(n=100, 50.8%) had age-adjusted mortality 23.2 (HR: 1.46, 95% CI, 0.98–2.18, P=.063), all-
cause hospitalization rate 53.5 (RR: 1.04, 95% CI 0.82–1.32, P=.74) and HF rehospitalization
rate 46.3 per 100 person-years (RR: 1.20, 95% CI 0.92–1.57, P=.18).
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In the current study, we found a high rate of incident HF in the elderly, poor prognosis for these
participants once they developed HF, and race related differences in risk factor profile for
incident HF. Considering the worsening risk factor profile for HF in the population (e.g.
diabetes, hypertension), aging of the population, and the increasing HF prevalence, our study
underscores the need for focused HF prevention efforts.
Heart Failure Incidence
The rate of incident HF in our study was similar to a recent study comprising of elderly
population 25; however these rates are lower as compared to data from administrative databases.
6, 26 Varying rates for incident HF have also been reported by the Framingham Heart Study,
the Cardiovascular Health Study, and from the Olmsted County, Minnesota.4, 5, 10 These
differences are likely related to different age groups, racial mix, geographic variation etc. from
which these cases were ascertained. Our study most likely underestimated HF rate as the
definition of incident HF required hospitalization and some patients with new onset HF may
not require hospitalization. Also, diagnosing HF is challenging and studies have used primarily
sign and symptoms; medication profile review; and cardiac imaging based assessment; some
studies have utilized chart reviews whereas others have used administrative databases. This
becomes more complicated when assessing HF with preserved ejection fraction as its signs
and symptoms are non-specific, there is no standard medication profile, and imaging
characteristics are complicated.
Irrespective of the precise quantitative assessment, several themes are similar across all these
studies, including a high incidence rate, worsening profile with aging, and either stagnant or
increasing incidence rates over the last several decades. These trends have tremendous
implications as the population demographics are changing. With the aging of the 78 million
baby boomers, 1 in 5 Americans are expected to be over 65 years by 2050.27 This trend is
projected to significantly impact healthcare and healthcare economics since the use of formal
and informal services strongly correlate with age. Without effective prevention efforts, the
current HF epidemic can be expected to significantly worsen in the near future.
Risk Factors for HF
Although risk factors for HF have been described, 10 those data have limitations as many are
older studies on primarily white younger participants. Many studies have assessed risk factors
in isolation rather than assessing their multivariable independent association. Risk factor
profile for cardiovascular diseases is changing with increasing obesity prevalence, and race
and sex related differences in risk factors and outcomes for incident HF in the elderly were not
assessed in these studies.12–14 In the current study, for example, most of the modifiable risk
factors were significantly more prevalent among blacks (compared to their white counterparts)
and constituted a major driving force for the higher incidence of heart failure in blacks. Lastly,
although literature on HF risk factors is rich, data on PAR are limited,28, 29 and only the
Cardiovascular Health Study has specifically addressed this issue.10
In the Cardiovascular Health Study, the investigators assessed PAR for all significant
associations with HF. Several of these maybe be collinear and hence may “dilute” the true
effect of modifiable risk factors. For example, CHD, ankle-arm index, carotid intima medial
thickness, stroke, and electrocardiographic evidence of ST-T wave changes were all included
in the analysis due to their statistical significance. They may however be related to a common
domain of vascular atherosclerosis as a risk factor. Indeed, the CHD attributable risk was only
13%. Assessment of PAR requires binary categorization of continuous variables; such
categorization was not based on clinically used cut-offs, e.g. C-reactive protein >7 mg/dl.
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Lastly, sex- or race- based analysis was not performed and we found significant differences in
this regard.
We observed that CHD and uncontrolled blood pressure were the leading causes of HF in both
race and sex based subgroups. We also observed that a substantial proportion of HF is attributed
to metabolic and cardio-renal factors, including glucose and renal abnormalities as described
previously 30, 31, and low albumin levels. It is not clear whether low albumin signifies cachexia,
inflammation, or comorbidity burden; or hypoalbuminemia precipitates symptomatic HF due
to fluid extravasation.32 Increased heart rate has been reported as a HF risk factor, and may
represent a surrogate of vasovagal imbalance or a physiologic response to worsening cardiac
function.33 Although much work is needed to assess which of these risk factors can be modified
and how much, if any, HF risk reduction may be achieved, it is still notable that most risk
factors were either modifiable or amenable to potential intervention.
Two observations regarding racial differences merit special comment. First, LVH appears to
affect mainly blacks, which is consistent with the high prevalence of uncontrolled blood
pressure in blacks. However, the risk associated with LVH was additive and independent from
that associated with uncontrolled blood pressure; in fact, LVH was encountered in 8.6% of
participants with systolic blood pressure <140mmHg. Second, the higher incidence of HF
observed in blacks is accompanied by a higher prevalence of modifiable risk factors and, thus,
a higher preventable fraction of incident HF. With the exception of increased fasting glucose,
PAR for all risk factors was higher in blacks, with 6 out of 8 assessed risk factors (CHD,
uncontrolled blood pressure, LVH, reduced GFR, smoking, and increased heart rate) having
>5% higher PAR.
Outcomes after HF Development
Despite the selection bias resulting in a relatively lower comorbidity burden compared to
general population, mortality after hospitalization for HF in the Health ABC Study was high
(annual rate 18.0%), similar to that reported by recent community-based studies.5, 8 In fact,
studies assessing temporal trends in mortality post-HF development demonstrate either none
or only modest improvements over the last few decades.8 These results suggest that either the
benefit from recent advances in HF therapy observed in “real-life” patient population are
significantly less than in the clinical trial setting; or that they may not have yet been translated
into routine clinical practice; or that HF characteristics at the community level are different
than those in clinical trials.
In concordance with a retrospective cohort study,34 we observed significantly higher all-cause
and HF readmission rates in blacks, whereas mortality did not differ overall across race; there
was however a race-sex interaction with black men presenting the highest mortality among
race-sex subgroups. Nevertheless, the latter finding should be interpreted with caution because
of the relatively small number of events.
Value of Population Attributable Risk
The PAR for a risk factor represents the proportional reduction in disease risk that would be
achieved by eliminating the risk factor from the population, assuming however a causal
relation. The relative importance of risk factors in the population as defined by PAR can help
guide policy makers in planning public health interventions. It has to be noted however, that
the absolute PAR estimates are highly dependent on the definition of risk factors and in the
multivariate setting also on the presence or absence of other risk factors.
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Diagnosis of incident HF in our study was based on HF hospitalization and therefore we likely
underestimated the true incidence. Echocardiography was not performed at baseline. Thus,
participants with subclinical prevalent structural heart disease may have been included in the
analysis. The Health ABC Study did not collect detailed data on valvular heart disease; however
it is unlikely that a very large proportion of participants had significant subclinical valvular
heart disease that would impact these results overall.29 Also, because ventricular function
during hospitalization for HF was not prospectively assessed, we could not reliably assess the
differential impact of risk factors on development of HF with preserved vs. reduced LVEF.
The available data on LVEF are based on chart reviews and do not refer to a single modality.
Therefore, we cannot be confident that the distribution of LVEF is representative of the elderly
population hospitalized with new-onset HF. Finally, the causes of the observed differences in
outcomes between groups cannot be ascertained in this study. These differences may represent
race, gender, severity of illness, or therapy related differences and need further study.
Conclusion
In this study we observed a high incidence for HF in the elderly. Race-based differences in risk
factors were noted. Outcomes after development of HF remain poor. However, most risk factors
for HF are either modifiable or potentially amenable to interventions. Therefore HF prevention
efforts may succeed in reducing the community-based burden of HF. Considering the
worsening risk factor profile and aging of the population, such efforts should be considered a
public health priority.
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Figure 1. Incident heart failure by sex and race
In the Health ABC cohort, men and blacks were more likely to develop HF than women and
whites (stratified log-rank χ2 for sex 7.30, P=.007; for race 7.85, P=.005).
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Figure 2. Mortality after incident heart failure by sex and race
Overall survival did not differ between whites and blacks; however, there was a statistically
significant race-sex interaction, with black men showing a higher mortality than white men
compared to their female counterparts.
Kalogeropoulos et al. Page 12




































Age, years 73.6 (2.9) 74.2 (2.9) 73.6 (2.9) .001
Males, % 47.9 54.3 47.3 .037
Whites, % 58.6 52.3 59.2 .034
Smoking status
 Current, % 10.5 17.1 9.9 0.02
 Past, % 45.0 44.7 45.0
Marital Status
 Never Married, % 5.1 5.8 5.1
 Married, % 54.5 49.2 55.1 .149
 Widowed, % 31.0 37.1 30.4
 Divorced/Separated, % 9.3 7.9 9.5
Education
 < than high school, % 10.6 10.2 10.7
 High school, % 40.8 41.8 40.7 .945
 Post high school, % 48.6 48.0 48.6
Body mass index, kg/m2 27.3 (4.8) 28.1 (4.9) 27.3 (4.8) .013
 <25 32.7 30.6 32.9
 25–30 41.9 36.4 42.5 .014
 >30 25.4 33.0 24.6
Systolic blood pressure, mmHg 136 (21) 144 (24) 135 (20) <.001
Systolic blood pressure >140mmHg,% 36.6 51.9 35.1 <.001
Diastolic blood pressure, mmHg 71 (12) 73 (13) 71 (12) .070
Heart rate, beats/minute 65 (11) 68 (12) 65 (11) .003
Heart rate >75 beats/minute, % 16.4 24.1 15.7 .001
Left ventricular hypertrophy, % 11.9 17.8 11.3 .003
Hypertension
 Definite,% 43.4 58.0 41.9 <.001
 Possible, % 10.1 10.9 10.0
Diabetes, % 14.8 23.4 13.9 <.001
Depression
 Definite, % 2.1 2.0 2.1 .608
 Possible, % 7.9 6.2 8.0
Cerebrovascular disease, % 6.8 9.9 6.5 .001
Coronary heart disease
 Definite, % 16.5 36.0 14.7 .001
 Possible, % 3.1 3.6 3.1
Glucose fasting, mg/dl 104 (34) 114 (46) 103 (33) <.001
Glucose fasting >125mg/dl, % 13.1 22.1 12.3 <.001
Creatinine, mg/dl 1.05 (0.41) 1.16 (0.58) 1.04 (0.39) .001






















eGFR, ml/min/1.73m2 73 (16) 70 (19) 73 (16) .035
eGFR <60 ml/min/1.73m2, % 20.5 28.1 19.7 .002
Albumin, g/dl 3.98 (0.31) 3.94 (0.32) 3.98 (0.31) .039
Albumin <3.8 g/dl, % 22.7 28.1 22.2 .041
Total cholesterol, mg/dl 203 (38) 198 (40) 204 (38) .030
High density lipoprotein, mg/dl 54 (17) 52 (17) 55 (17) .012
Low density lipoprotein, mg/dl 122 (35) 119 (35) 122 (35) .255
Triglycerides, mg/dl 137 (77) 134 (70) 137 (78) .527
Continuous variables are expressed as mean (SD).
eGFR=estimated glomerular filtration rate




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Arch Intern Med. Author manuscript; available in PMC 2009 October 5.
